We’re proud to announce that Seva has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Total Product Life Cycle Advisory Program (TAP) Pilot. TAP is a voluntary program designed to facilitate more efficient development and approval of medical devices.
This opportunity positions Seva as one of the first organizations to contribute to expanding this program into ophthalmic devices in 2025. As a TAP Pilot member, Seva will leverage its extensive experience to guide strategic decision-making and accelerate innovations that align with our mission to improve access to vision care around the globe.
“Investing in new technologies to further eye care access is one of the Seva Foundation’s key drivers for success. Our involvement in the TAP Pilot is a meaningful step for Seva, as together with manufacturers, we can advance solutions that help end avoidable blindness and provide everyone the chance to see the world clearly.”
– Kate Moynihan
CEO/Executive Director
This collaboration isn’t just a win for Seva – it’s a leap forward for vision care worldwide.
